Stoke Therapeutics (STOK) Non-Current Assets (2018 - 2026)

Stoke Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at $76.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 145.88% year-over-year to $76.6 million; the trailing twelve-month figure through Mar 2026 stood at $391.7 million (up 225.27% YoY), and the FY2025 full-year result was $112.7 million, up 190.56% from the prior year.
• Non-Current Assets for Q1 2026 stood at $76.6 million, down from $112.7 million in the prior quarter.
• The five-year high for Non-Current Assets was $114.5 million in Q2 2025, with the low at $9.9 million in Q3 2023.
• Average Non-Current Assets over 5 years is $36.3 million, with a median of $13.0 million recorded in 2023.
• Year-over-year, Non-Current Assets decreased 24.22% in 2023 and surged 964.18% in 2025.
• Tracing STOK's Non-Current Assets over 5 years: stood at $12.0 million in 2022, then increased by 8.39% to $13.0 million in 2023, then soared by 198.38% to $38.8 million in 2024, then jumped by 190.56% to $112.7 million in 2025, then tumbled by 32.06% to $76.6 million in 2026.
• The last three Non-Current Assets figures came in at $76.6 million (Q1 2026), $112.7 million (Q4 2025), and $87.8 million (Q3 2025), per Business Quant data.

Peer Comparison